<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974584</url>
  </required_header>
  <id_info>
    <org_study_id>GDC4628g</org_study_id>
    <secondary_id>GO01303</secondary_id>
    <nct_id>NCT00974584</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety,
      tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three
      planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients,
      Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and
      Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Days 1 to 22 of Cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Paclitaxel</measure>
    <time_frame>Cycle 1 Day 2: Pre-paclitaxel infusion, end of paclitaxel infusion, 0.5, 1 and 2 hours post-paclitaxel infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-paclitaxel Day 2 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Carboplatin</measure>
    <time_frame>Cycle 1 Day 2: Pre-carboplatin infusion, end of Carboplatin infusion, 0.5, 1.5 hours post-carboplatin infusion\n\n</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Pemetrexed</measure>
    <time_frame>Cycle 1 Day 2: Pre-pemetrexed infusion, end of pemetrexed infusion, 1, 3 hours post-pemetrexed infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-pemetrexed Day 2 infusion\n\nd be &quot;Yes&quot;.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Cisplatin</measure>
    <time_frame>Cycle 1 Day 2: Pre-cisplatin infusion, end of cisplatin infusion, 3 hours post-cisplatin infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-pemetrexed Day 2 infusion\n\n</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response (Complete or Partial Response), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)\n\n</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, as Assessed Using RECIST\n\n\n</measure>
    <time_frame>Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS), as Assessed Using RECIST\n</measure>
    <time_frame>Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)\n\n</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of GDC-0941</measure>
    <time_frame>Cycle 1 Days 1 and 2: Pre-GDC-0941 dose, 1, 2, 3 and 4 hours post-GDC-0941 dose; Cycle 1 Days 3 and 9: Pre-GDC-0941 dose; 30 days after last dose of study treatment (up to approximately 5.5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n</description>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin</arm_group_label>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin+Bevacizumab</arm_group_label>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.</description>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin+Bevacizumab</arm_group_label>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n</description>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin</arm_group_label>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n</description>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n</description>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin</arm_group_label>
    <arm_group_label>GDC-0941+Paclitaxel+Carboplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.</description>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>GDC-0941+Pemetrexed+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented NSCLC with advanced disease (Stage IIIb not
             eligible for chemoradiotherapy or Stage IV or recurrent disease)

          -  Adequate organ function as assessed by laboratory tests

          -  Evaluable disease or disease measurable per Response Evaluation Criteria in Solid
             Tumors (RECIST)

        Exclusion Criteria:

          -  More than one anti-cancer regimen (chemotherapy or radiotherapy) for advanced NSCLC
             prior to initiation of study treatment

          -  Any adjuvant or neoadjuvant anti-cancer therapy within a specified timeframe prior to
             first study treatment

          -  History of Grade &gt;= 3 fasting hyperglycemia or diabetes requiring regular medication

          -  Active autoimmune disease, active infection requiring IV antibiotics, or other current
             uncontrolled illness

          -  History of clinically significant cardiac or pulmonary dysfunction

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Clinically significant history of liver disease

          -  Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or
             thrombolytic agents

          -  Known brain metastases that are untreated, symptomatic, or require therapy

          -  Pregnancy, lactation, or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>PI3K</keyword>
  <keyword>Avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

